Subsequently, it also destroys actin depolymerization and migration.202 The ability of cancer cells to migrate and invade requires a recombinant actin cytoskeleton,203 while Rac1 is the main regulator of the actin cytoskeleton.204 Many other studies have also shown that Rac1 is overexpressed in many cancers, and the loss of Rac1 activity inhibits tumor growth.205,206 In addition, Uro-A can lead to a dose-dependent anti-cloning effect by increasing the aging-related β-galactosidase activity.207 Therefore, the application of urolithin A in cancer prevention or adjuvant therapy is promising. This evidence concerns the gene RAC1 and cancer.